DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more



Gabapentin for the Treatment of Hot Flashes in Menopausal Women

Information source: North Toronto Primary Care Research Network
ClinicalTrials.gov processed this data on August 20, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Hot Flashes; Menopause

Intervention: gabapentin (Drug)

Phase: Phase 3

Status: Completed

Sponsored by: North Toronto Primary Care Research Network

Official(s) and/or principal investigator(s):
Debra Butt, MSc MD CCFP, Principal Investigator, Affiliation: North Toronto Primary Care Research Network

Summary

The purpose of this study is to evaluate the effectiveness and safety of gabapentin compared to placebo in the treatment of hot flashes in postmenopausal women using a phase III randomized controlled trial.

Clinical Details

Official title: Effectiveness and Safety of Gabapentin for the Treatment of Hot Flashes in Menopausal Women: A Randomized Controlled Trial

Study design: Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double-Blind, Primary Purpose: Treatment

Primary outcome: Compared to placebo, gabapentin effectiveness in reducing hot flash scores in postmenopausal women

Secondary outcome:

The toxicity profile of gabapentin in this population compared with placebo

The impact of gabapentin on quality of life in this population compared with placebo

Correlation of the Menopause-specific Quality of Life (MENQOL) results with the change in hot flash scores

Detailed description: For women who fear developing breast cancer, those who have contraindications to hormone replacement therapy and those who prefer an alternative treatment, there is presently no standard treatment for hot flashes. Women and health care providers have few options other than hormone replacement therapy as evidenced-based trials of alternatives have not shown many effective options. Many non-hormonal agents have been studied including antidepressants, antihypertensives, vitamin E, soy products, black cohosh, acupuncture, and belladonna and ergotamine combinations. Preliminary studies using the antiseizure medication, gabapentin (Neurontin), has demonstrated a substantial reduction in hot flashes. This agent may provide an effective treatment for hot flashes in postmenopausal women.

Eligibility

Minimum age: 45 Years. Maximum age: 65 Years. Gender(s): Female.

Criteria:

Inclusion Criteria:

- Women with substantial hot flashes defined as reporting at least 14 hot flashes per

week.

- Postmenopausal women as defined by the natural cessation of menses for 1 year.

- Aged 45 - 65 years.

Exclusion Criteria:

- Women on hormone replacement therapy.

- Women with a surgically induced menopause (oophorectomy).

- Women on tamoxifen or receiving chemotherapy/radiation therapy or planned

antineoplastic chemotherapy/radiation therapy.

- Renal function impairment (serum creatinine greater than the laboratory normal range;

or creatinine clearance <30ml/min).

- Use of antidepressants with serotonin reuptake mechanisms and antiseizure medications

within the past month.

- Neurologic conditions: seizures, vertigo, and syncope.

- Known hypersensitivity to gabapentin and its components.

- Inability to complete questionnaires for any reason including psychiatric disorders.

- History of a hypothalamic dysfunction.

- Life expectancy less than 6 months.

Locations and Contacts

The Scarborough Hospital, Scarborough, Ontario M1P 2V5, Canada
Additional Information

Related publications:

Guttuso T Jr, Kurlan R, McDermott MP, Kieburtz K. Gabapentin's effects on hot flashes in postmenopausal women: a randomized controlled trial. Obstet Gynecol. 2003 Feb;101(2):337-45.

Starting date: March 2004
Last updated: May 20, 2011

Page last updated: August 20, 2015

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017